Definium Therapeutics (NASDAQ:DFTX) Shares Gap Up – Should You Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares gapped up before the market opened on Wednesday . The stock had previously closed at $40.91, but opened at $47.51. Definium Therapeutics shares last traded at $42.85, with a volume of 2,741,718 shares changing hands.

More Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium announced positive topline results from the Phase 3 Voyage study, saying DT120 ODT reduced anxiety symptoms in patients with generalized anxiety disorder. The study is the second of two positive Phase 3 trials for the therapy, providing important validation for the program and supporting investor expectations for a future filing. Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study
• Positive Sentiment: Coverage characterized the result as another successful late-stage study for Definium’s LSD-based anxiety drug, triggering a strong rally in the biotech stock. Investors are likely focusing on the potential size of the anxiety-treatment market and the reduced clinical risk following two positive Phase 3 outcomes. This LSD-Based Drug Just Scored Again. Definium Stock Soars.
• Neutral Sentiment: Trading in DFTX was temporarily halted for pending news before the clinical announcement. Such halts can increase short-term volatility but do not independently alter the company’s fundamentals.
• Neutral Sentiment: Reports published before the trial announcement said investors were awaiting the anxiety data and that the stock faced the possibility of its worst session in months. The subsequent positive results superseded that immediate concern. DFTX stock on track for worst day in 9 months as investors brace for anxiety trial data
• Negative Sentiment: HC Wainwright cut its EPS forecasts across 2026-30, including reducing its FY2026 estimate to a loss of $3.05 per share from $2.10 and its FY2027 estimate to a loss of $1.71 from $1.22. The revisions underscore that Definium remains loss-making and that near-term spending and commercialization timing remain risks, despite the clinical progress.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on DFTX shares. Robert W. Baird boosted their price objective on shares of Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, June 23rd. JonesTrading raised their price target on shares of Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a report on Wednesday, June 24th. Royal Bank Of Canada restated an “outperform” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Piper Sandler reissued an “overweight” rating and set a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a research note on Friday, August 7th. Finally, Oppenheimer set a $60.00 target price on Definium Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Definium Therapeutics currently has a consensus rating of “Buy” and an average price target of $55.00.

Definium Therapeutics Stock Up 7.7%

The stock’s fifty day moving average price is $38.68 and its 200 day moving average price is $26.34. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The stock has a market cap of $4.39 billion, a P/E ratio of -12.84 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, research analysts forecast that Definium Therapeutics, Inc. will post -2.65 earnings per share for the current fiscal year.

Insider Transactions at Definium Therapeutics

In other news, insider Matthew T. Wiley sold 2,867 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the transaction, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. This represents a 1.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Brandi Roberts sold 3,013 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares in the company, valued at approximately $9,433,199.61. This represents a 1.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 48,096 shares of company stock valued at $2,165,763 over the last quarter. 2.40% of the stock is owned by company insiders.

Institutional Trading of Definium Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada lifted its stake in shares of Definium Therapeutics by 10.4% in the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after purchasing an additional 6,148 shares during the period. Creative Planning grew its stake in Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after purchasing an additional 1,655 shares during the period. JPMorgan Chase & Co. raised its holdings in Definium Therapeutics by 5.1% in the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock worth $315,000 after purchasing an additional 2,342 shares in the last quarter. Rhumbline Advisers raised its holdings in Definium Therapeutics by 6.3% in the second quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock worth $748,000 after purchasing an additional 6,839 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares in the last quarter. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.